XML 51 R40.htm IDEA: XBRL DOCUMENT v3.25.3
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 28, 2025
Sep. 29, 2024
Sep. 28, 2025
Sep. 29, 2024
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     $ 2,120  
Provision [2] $ 237 $ 217 784 $ 1,331
Utilization and other [3]     (1,067)  
Balance, ending [4] 1,836   1,836  
Other Current Liabilities [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning     1,700  
Balance, ending 1,300   1,300  
Other Noncurrent Liabilities [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning     437  
Balance, ending 532   532  
Employee Termination Costs [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     2,046  
Provision     360  
Utilization and other [3]     (724)  
Balance, ending [4] 1,682   1,682  
Asset Impairment Charges [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     0  
Provision     328  
Utilization and other [3]     (328)  
Balance, ending [4] 0   0  
Exit Costs [Member]        
Restructuring Reserve [Roll Forward]        
Balance, beginning [1]     74  
Provision     96  
Utilization and other [3]     (15)  
Balance, ending [4] $ 155   $ 155  
[1] Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($437 million).
[2] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $240 million for the three months ended September 28, 2025 (including charges of $117 million for our Manufacturing Optimization Program and charges of $107 million for our Realigning our Cost Base Program), (ii) charges of $451 million for the nine months ended September 28, 2025 (including charges of $669 million for our Realigning our Cost Base Program and credits of $295 million for our Manufacturing Optimization Program), (iii) charges of $141 million for the three months ended September 29, 2024 (primarily including charges for our Realigning our Cost Base Program) and (iv) charges of $1.2 billion for the nine months ended September 29, 2024 (including charges of $1.3 billion for our Manufacturing Optimization Program and credits of $69 million for our Realigning our Cost
Base Program). For the nine months ended September 28, 2025 and September 29, 2024, Employee terminations include revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.
[3] Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.
[4] Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($532 million).